



Universiteit
Leiden
The Netherlands

Differentiated thyroid carcinoma : treatment and clinical consequences of therapy

Hoftijzer, H.C.

Citation

Hoftijzer, H. C. (2011, May 12). *Differentiated thyroid carcinoma : treatment and clinical consequences of therapy*. Retrieved from <https://hdl.handle.net/1887/17641>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17641>

Note: To cite this publication please use the final published version (if applicable).



Differentiated Thyroid Carcinoma

treatment and clinical consequences of therapy

Hendrieke C. Hoftijzer



Differentiated Thyroid Carcinoma
treatment and clinical consequences of therapy

Lay out & Cover design: Pieter Vos

Printed by: Optima Grafische Vormgeving, Rotterdam

ISBN 978-94-6169-032-6

This research was financially supported by
Bayer Healthcare B.V. Mijdrecht, the Netherlands
ZonMw-AGIKO grant

Publication of this thesis was financially supported by Bayer Healthcare B.V., Novo Nordisk B.V., Servier Nederland Farma B.V., Merck Sharp & Dohme B.V., Genzyme Europe B.V., AstraZeneca B.V., Ipsen Farmaceutica B.V., Novartis Pharma B.V., J.E. Jurriaanse Stichting

Differentiated Thyroid Carcinoma

treatment and clinical consequences of therapy

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 12 mei 2011
klokke 15.00 uur

door

Hendrieke Catherijn Hoftijzer

geboren te Schiedam

in 1980

Promotiecommissie

Promotores	Prof. Dr. J.W.A. Smit	LUMC
	Prof. Dr. J.A. Romijn	LUMC
Copromotor	Dr. E.P.M. van der Kleij-Corssmit	LUMC
Overige leden	Prof. Dr. T.P. Links	UMCG
	Prof. Dr. J. Kievit	LUMC
	Prof. Dr. J. Morreau	LUMC
	Prof. Dr. T.J. Visser	Erasmus MC
	Prof. Dr. J.H. Bolk	LUMC

Contents

Chapter 1.	General introduction	7
Chapter 2.	Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms	47
Chapter 3.	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma	63
Chapter 4.	Sorafenib induced hypothyroidism is associated with increased type 3 deiodination	83
Chapter 5.	The type 2 deiodinase Thr92Ala polymorphism is not associated with T4 dose in athyroid patients treated for differentiated thyroid carcinoma or patients with Hashimoto thyroiditis	93
Chapter 6.	The type 2 deiodinase ORFa-Gly3Asp polymorphism influences the setpoint of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma	103
Chapter 7.	The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density	117
Chapter 8.	Thyroid hormone rather than TSH decreases bone turnover during hypothyroidism in athyroid patients with differentiated thyroid carcinoma	133
Chapter 9.	Short term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinoma	147
Chapter 10.	Quality of life in cured patients with differentiated thyroid carcinoma	161
Chapter 11.	General discussion and summary	173
Chapter 12.	Nederlandse samenvatting	197
Chapter 13.	List of publications	213
Chapter 14.	Curriculum vitae	217

